| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 12/06/2001 | CA2410433A1 Method of forming vertebrate pancreas in vitro |
| 12/06/2001 | CA2410015A1 Methods of transducing neural cells using lentivirus vectors |
| 12/06/2001 | CA2409932A1 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | CA2409359A1 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | CA2401974A1 Dna expression vectors and methods of use |
| 12/05/2001 | EP1159966A2 Composition for the treatment of psoriasis |
| 12/05/2001 | EP1159951A1 Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases |
| 12/05/2001 | EP1159439A2 Enhanced system for construction of adenovirus vectors |
| 12/05/2001 | EP1159420A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 12/05/2001 | EP1159409A1 Introducing a biological material into a patient |
| 12/05/2001 | EP1159404A2 Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| 12/05/2001 | EP1159403A2 The isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression |
| 12/05/2001 | EP1159300A2 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159002A2 Emulsan and emulsan analogs immunization formulations and use |
| 12/05/2001 | EP1158999A2 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 12/05/2001 | EP1158993A1 Bacterial membrane fractions with adjuvant effect |
| 12/05/2001 | EP1158938A1 In vitro production of transplantable cartilage tissue |
| 12/05/2001 | EP1011699B1 Galactosidase modified submucosal tissue |
| 12/05/2001 | EP0910393B1 Agent for the topical treatment of skin conditions |
| 12/05/2001 | EP0814820B1 Method and apparatus for harvesting blood components |
| 12/05/2001 | EP0605581B1 Graft for promoting autogenous tissue growth |
| 12/05/2001 | EP0605432B1 Induction of cytolytic t-lymphocytes with cytomegalovirus polypeptides |
| 12/05/2001 | CN1325453A Vancoresmycin, a process for its production and its use as a pharmaceutical |
| 12/05/2001 | CN1325451A Recombinant adevovirus for tissue specific expression in heart |
| 12/05/2001 | CN1325450A Adenovirus-mediated gene therapy |
| 12/05/2001 | CN1325271A Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 12/05/2001 | CN1324864A Trivalent chromium compound and its milk product and making process |
| 12/05/2001 | CN1324656A Chinese medicine prepn. with immunity strengthening effect |
| 12/05/2001 | CN1324654A Cold eliminating pellet |
| 12/05/2001 | CN1324647A Prepn. of hematopoietic tortoise-deer capsule |
| 12/05/2001 | CN1324639A Medicine for treating urinary tract calculus |
| 12/05/2001 | CN1324633A Hyperosteogeny-treating capsule |
| 12/05/2001 | CN1324627A Diabetes treating medicine and its prepn. method |
| 12/05/2001 | CN1324622A Bone-strengthening and pus-drawing out ointment |
| 12/05/2001 | CN1324621A Production process of obtaining non-toxic effective buthotoxin |
| 12/05/2001 | CN1324620A production process of biological active toad capsule |
| 12/05/2001 | CN1324619A Health capsule of pure active chitosan and animal fiber |
| 12/05/2001 | CN1075734C Medicine for treating hyperosteogeny |
| 12/05/2001 | CN1075733C Face-nourishing oral liquor and its preparation method |
| 12/05/2001 | CN1075730C Wind-dispelling meridian passage-dredging and pus-drawing out medicinal powder |
| 12/05/2001 | CN1075729C Hypoglycemic paste |
| 12/05/2001 | CN1075727C Capsule for treating nervous lesion and production method thereof |
| 12/05/2001 | CN1075724C Suppository for curing prostatosis |
| 12/04/2001 | US6326504 Solvent extraction using supercritical fluid |
| 12/04/2001 | US6326473 Pharmaceutical preparations |
| 12/04/2001 | US6326464 Genetically engineered tumor suppressor protein; for use in the treatment of cancers; antiproliferative agents |
| 12/04/2001 | US6326356 Antitumor agents |
| 12/04/2001 | US6326205 Methods for use of Mpl ligands with primitive human stem cells |
| 12/04/2001 | US6326201 Isolating stem cells of pancreas; obtain pancreatic tissue, dissociate and obtain pancreatic duct tissue, culture, isolate stem cells cells |
| 12/04/2001 | US6326197 Platelet suspensions and methods for resuspending platelets |
| 12/04/2001 | US6326195 Recombinant retroviral vector |
| 12/04/2001 | US6326031 Method of decreasing cholesterol and triglycerides levels with a composition containing fish oil, garlic, rutin, and capsaicin |
| 12/04/2001 | US6326019 Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
| 12/04/2001 | US6326018 Flexible sheet of demineralized bone |
| 12/04/2001 | US6326009 Parenterally administering carbohydrate antigenic primer (determinant) bearing antigen; conjugated to animmunogenic carrier |
| 12/04/2001 | US6326001 Recombinant vaccine for diseases caused by encapsulated organisms |
| 12/04/2001 | US6326000 Kit with enteral dietary composition consisting of Streptococcus thermophilus, Bifidobacterium infantis and Bifidobacterium longum |
| 12/04/2001 | US6325999 Use of Fas ligand to suppress T-lymphocyte-mediated immune responses |
| 12/04/2001 | US6325998 Methods of treating disease using recombinant adeno-associated virus virions administered to muscle |
| 12/04/2001 | CA2024253C Entities for cancer therapy |
| 11/29/2001 | WO2001090759A2 Diagnostic method for hyperinsulinism of infancy based on detecting altered k-atp channels |
| 11/29/2001 | WO2001090390A1 Use of baculovirus vectors in gene therapy |
| 11/29/2001 | WO2001090347A1 Antiviral antisense therapy |
| 11/29/2001 | WO2001090342A2 Genetic engineering of vascular grafts to resist disease |
| 11/29/2001 | WO2001090319A2 Fructosyltransferases (inulosucrase and levansucrase) from lactobacillus reuteri |
| 11/29/2001 | WO2001090316A2 Human circulating dendritic cell compositions and methods |
| 11/29/2001 | WO2001090315A2 Production of neurons from stem cells |
| 11/29/2001 | WO2001090311A1 Novel probiotics for pet food applications |
| 11/29/2001 | WO2001090306A2 Compositions and methods for modulating tumor specific expression |
| 11/29/2001 | WO2001090153A2 Reagents for cell selection and methods of use |
| 11/29/2001 | WO2001090152A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 11/29/2001 | WO2001089593A1 Transfection system |
| 11/29/2001 | WO2001089568A1 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 11/29/2001 | WO2001089548A2 Pharmaceutical use of fibulin-1 |
| 11/29/2001 | WO2001089541A1 Use of lactobacillus casei in immunostimulatory peptides |
| 11/29/2001 | WO2001089540A1 Use of egg white and egg white fractions for tissue regeneration |
| 11/29/2001 | WO2001089539A2 Methods for restoring or enhancing t-cell immune surveillance following naturally or artifically induced immunosuppression |
| 11/29/2001 | WO2001089538A2 Apoptotic entities for use in treatment of endothelium dysfunction disorders |
| 11/29/2001 | WO2001089537A2 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| 11/29/2001 | WO2001089536A2 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders |
| 11/29/2001 | WO2001089486A1 Nonoral preparation having three-layer structure |
| 11/29/2001 | WO2001062284A3 Novel method for down-regulation of amyloid |
| 11/29/2001 | WO2001060810B1 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity |
| 11/29/2001 | WO2001044458A3 Bovine immunodeficiency virus (biv) based vectors |
| 11/29/2001 | WO2001042471A8 Polypeptides and polynucleotides encoding same |
| 11/29/2001 | WO2001040451A3 Masp-3, a complement-fixing enzyme, and uses for it |
| 11/29/2001 | WO2001038566A3 Screening method for candidate drugs |
| 11/29/2001 | WO2001030980A3 Methods and compositions for enhancing developmental potential of oocytes and zygotes |
| 11/29/2001 | WO2001029234A3 Self-cleaving rna sequences and their use for the control of protein synthesis |
| 11/29/2001 | WO2000073469A3 Protein kinases |
| 11/29/2001 | US20010047085 Adding to the protein solution a cyclodextrin in an amount sufficient to form a stable complex with the protein, lyophilizing, recovering lyophilized protein/cyclodextrin complex, heating complex to inactivate viruses |
| 11/29/2001 | US20010046962 Presynaptic neurotoxin such as botulinum toxin A |
| 11/29/2001 | US20010046697 Bacillus natto culture extract |
| 11/29/2001 | US20010046524 Administering to the patient a formulation comprising an extract of Eucommia ulmoides (plant extract) or an extract of botanical equivalent of Eucommia extract or acomponent to modulalte steroid-mediated physiological condition |
| 11/29/2001 | US20010046489 Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
| 11/29/2001 | US20010046488 Compositions and methods for delivery of an organized tissue to an organism |
| 11/29/2001 | US20010046487 Permeabilizing platelets by acid treatment; temperature and aging resistance |
| 11/29/2001 | US20010046486 Stimulation of thymus for vaccination development |
| 11/29/2001 | US20010046450 Irradiation of blood with type c ultraviolet light, deactivating viruses |